Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc (NQ: BEAM )

26.65 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling more than 50 points on Tuesday. Here are some major stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
After Cutting 20% of Its Staff, Is Beam Therapeutics Still a Buy?
Some of the strategic shifts proposed by management are for the better. 
Via The Motley Fool
Why Beam Therapeutics Stock Is Getting Bought Today
Beam Therapeutics Inc (NASDAQ: BEAM) shares are trading higher Tuesday after Eli Lilly And Co (NYSE: LLY) agreed to acquire certain rights under Beam's  
Via Benzinga
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease
Beam to Receive $250 Million in Combined Upfront Payment and Equity Investment, Expected to Extend Beam’s Cash Runway to the Second Half of 2026 
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood Loves This Beaten-Down Stock. But Is It in Trouble?
Beam Therapeutics' pipeline will look slimmer going forward. 
Via The Motley Fool
Cathie Wood's Ark Invest Scoops Up More Than $3M Worth Of SoFi Technologies Shares Amid Q3 Earnings Beat From Online Lender
Via Benzinga
Topics Earnings
Exposures Financial
5 Reasons Beam Therapeutics Remains a Risky Stock
Shares of the gene-editing biotech might not have hit rock bottom yet. 
Via The Motley Fool
Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT
From Beam Therapeutics
Via GlobeNewswire
Textainer Group, Roivant Sciences And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
What's Going On With Beam Therapeutics Stock Thursday?
Beam Therapeutics Inc (NASDAQ: BEAM) shares are trading lower Thursday. 
Via Benzinga
Analyst Expectations for Beam Therapeutics's Future
Via Benzinga
2 Cathie Wood Stocks I'm Bullish On
These two next-gen biotechs could be outstanding buys for patient investors. 
Via The Motley Fool
Beam Therapeutics Stock: Bear vs. Bull
This biotech has a few factors in its corner, but it also faces a difficult path. 
Via The Motley Fool
Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers 
Via Benzinga
Investors Unpack Home Sales Data Ahead Of Fed Speech
Stocks are lower across the board, as investors unpack this morning's jobs and manufacturing data and await commentary from Federal Reserve Chairman Jerome Powell. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline
From Beam Therapeutics
Via GlobeNewswire
3 Gene Editing Stocks to Generate Super-Charged Gains
As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks. 
Via InvestorPlace
1 Risky Biotech Stock to Consider Buying, and 1 to Avoid
Both are in a race against time to commercialize a medicine before cash runs out. 
Via The Motley Fool
Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?
The Internet's most famous innovation-focused investor is excited about this company's innovative approach to editing the human genome. 
Via The Motley Fool
Cathie Wood's Ark Invest Sells Nearly $4M Worth Of NVIDIA Shares — Does It Herald Shift To Undervalued AI Gems?
On Monday, Cathie Wood-led Ark Invest made a notable move by selling nearly $4 million worth of NVIDIA Corp (NASDAQ:NVDA) shares. This ... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The iconic money manager has struggled the last two months. Let's see what she's buying to get back on track. 
Via The Motley Fool
Cathie Wood's Ark Invest Tweaks Portfolio, Sells $1.8M Worth Of DraftKings Shares
Via Benzinga
2 Magnificent Growth Stocks to Buy On the Dip
It might be time to catch these falling knives. 
Via The Motley Fool
3 Stocks Cathie Wood Is Buying That Should Be on Your List, Too
Cathie Wood is loading up on these healthcare stocks. 
Via The Motley Fool
2 Cutting-Edge Gene-Editing Stocks That You Don't Want to Miss
The gene-editing market is moving fast, and it pays to get to know some of these companies. 
Via The Motley Fool
Here's the 1 Cathie Wood Stock Most Likely to Turn $100,000 Into $1 Million Over the Next 20 Years
There's no guarantee that any stock will be a millionaire-maker. But the chances for this one look pretty good. 
Via The Motley Fool
This Cathie Wood Stock Is Down 40% in 2023. Here's Why She's Still Buying It.
The decline of Beam's stock says little about its long-term potential, according to Wood. 
Via The Motley Fool
Cathie Wood's Buying These 3 Stocks Hand Over Fist
A drugmaker, a gene sequencer, and a streaming business all made deep impressions on Ark Invest's stock-picking team. 
Via The Motley Fool
Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation
First Preclinical Data for BEAM-302 Demonstrate Increased Levels of Corrected AAT and Reduced Mutant PiZ AAT in Multiple In Vivo Rodent Disease Models 
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood's Ark Invest Keeps Shedding Shopify Nvidia Shares, Loads Up On Spotify Stock
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.